Insider buying last 90 days
No open-market insider purchases were filed for PVLA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PVLA insider filing, plotted on the chart in Gekko.Open PVLA in Gekko
NASDAQ: PVLA
Palvella Therapeutics (PVLA) Stock Analysis & Forecast
Oct 12 close
$134.38−4.39 (−3.2%)
Gekko Brief
AI summaryOct 12 closePalvella Therapeutics moved this week on continued momentum from its Phase 3 SELVA study, with three poster presentations at the Fall Clinical Dermatology Conference 2026 highlighting new data for microcystic lymphatic malformations and disseminated superficial actinic porokeratosis, including an estimate of 154,986 U.S. DSAP patients. This follows the stock's nearly 37% surge on positive topline Phase 3 SELVA results for QTORIN 3.9% rapamycin anhydrous gel, and reporting that the company is preparing for a potential U.S. launch in early 2027, having completed its FDA application and secured a third year of federal grant funding for the trial.
PVLA closed at $134.38, down 3.2%, sitting between its 50-day average of $147.53 and 200-day average of $124.76, with one-month and three-month returns of -10.5% and -10.2% against a one-year return of 91.7%. The GekkoIndex reads 64.1, in the Accumulation zone, though down 5.9 over five days. The stock trades 19.3% below its Gekko Fair Value of $166.52.
Palvella's next earnings are due 10 November 2026, before the open, 29 days away and inside a typical 20-trading-day holding window; its last report showed an actual EPS of -1.52 against an estimate of -1.17, with a 10% reaction, and the company has beaten estimates in 3 of its last 8 quarters. Nine analysts carry a consensus target of $230.53, all rated buy, with no hold or sell ratings. No insider, Congress, or options activity appears in the respective windows, though one trailblazer holder is noted.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Palvella Therapeutics price vs fair value
Close $134.38200-day averageGekko Fair Value $166.52
Palvella Therapeutics quick facts
- Market cap
- $1.93B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.85
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- —
- Volume
- 210,296 avg 234,422
- 1-year return
- +91.7%
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±13.4%
- 50-day average
- $147.53
- 200-day average
- $124.76
- Next earnings
- Nov 10 before open
- Shares outstanding
- 14.41M
Palvella Therapeutics swing-trade checklist
Palvella Therapeutics scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $134.38 sits between the 50-day ($147.53) and 200-day ($124.76) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.1, Accumulation
Reading 64.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
19.3% below
Price is 19.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 29 days
Reports on Nov 10, 2026, 29 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Palvella Therapeutics stock chart and price history
Palvella Therapeutics closed at $134.38 on Oct 12, 2026, +91.7% over the past year, inside a 52-week range of $65.93 to $161.38.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.5%
- 3 months
- −10.2%
- 6 months
- +4.2%
- 1 year
- +91.7%
The full PVLA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PVLA in Gekko
Follow Palvella Therapeutics through every session
Put PVLA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PVLA in GekkoFree for 7 days. No credit card required.
About Palvella Therapeutics
Palvella Therapeutics works on medicines for rare, serious skin conditions that patients are born with, rather than offering products already on the market. Its main focus is a treatment called QTORIN rapamycin, a topical gel being studied as a therapy for people whose skin disorders stem from problems in the mTOR biological pathway.
This gel is furthest along as a potential treatment for microcystic lymphatic malformations, where it has reached Phase 3 testing, and it is also being studied in Phase 2 trials for cutaneous venous malformations. Alongside these two programs, the company is looking at whether the same drug could help with other skin diseases linked to mTOR activity, suggesting a strategy built around one compound applied to several related conditions. As a clinical-stage business, its activities center on research and trials for patients with these inherited conditions rather than generating product sales.
Palvella Therapeutics is headquartered in Wayne, Pennsylvania, and its shares trade on the NASDAQ under the ticker PVLA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- palvellatx.com
Palvella Therapeutics GekkoIndex: the smart money zone
Palvella Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.1, in the Accumulation zone, down 5.9 points over five sessions.
64.1Accumulation
Down 5.9 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | Not available | |||
| Accumulation (current zone) | 98 | Not available | |||
| Neutral | 288 | +2.1% | +8.1% | ||
| Distribution | 49 | +5.7% | +16.4% | ||
| Selling | 4 | Too few readings yet | |||
Average PVLA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PVLA price, zone by zone.Track PVLA in Gekko
Is Palvella Therapeutics stock overvalued? Gekko Fair Value
Palvella Therapeutics trades 19.3% below Gekko Fair Value of $166.52, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Palvella Therapeutics shares are worth, recalculated every trading day.
$166.52
Gekko Fair Value, Oct 10, 2026
19.3% Undervalued
At the end of Aug 2026 the price was 24.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PVLA in Gekko
Palvella Therapeutics insider and Congress trading
No open-market insider purchases were filed for Palvella Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PVLA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PVLA, plotted on the chart in Gekko.Open PVLA in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PVLA.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Palvella Therapeutics earnings: next date and track record
Palvella Therapeutics reports on Nov 10, 2026, before the open (29 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 10, 2026
Expected before the open, 29 days away
- EPS estimate
- −$1.80
- Revenue estimate
- $17K
3 of 8reports beat the EPS estimate
±8.1%average move across the report
3 of 5reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Palvella Therapeutics achieved three major Q2 2026 milestones for QTORIN rapamycin in microcystic lymphatic malformations: positive Phase III SELVA study results, FDA rolling review designation, and first NDA module submission. The company targets four rare skin/vascular diseases with no approved treatments, estimating combined TAM of multi-billion dollars across 30,000-75,000 diagnosed U.S. patients per indication. Pipeline includes Fast Track designations for venous malformations and angiokeratomas programs.
- Guidance
- NDA submission remains on track for second half of 2026, with potential FDA approval targeted for first half of 2027. Commercial launch preparations are advancing with rare disease and dermatology leadership recruited.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$1.52 est −$1.17 | — | +10.0% |
| May 7, 2026 | −$1.20 est −$0.90 | — | −6.8% |
| Nov 11, 2025 | −$1.03 est −$0.85 | — | +1.6% |
| Aug 14, 2025 | −$0.86 est −$0.78 | — | +6.0% |
| Mar 31, 2025 | $4.00 est −$0.39 | — | −16.0% |
| Nov 13, 2024 | −$1.18 est −$4.00 | — est $1.07M | — |
| Aug 14, 2024 | −$2.76 est −$2.40 | — est $2.24M | — |
| May 16, 2024 | −$2.00 est −$4.80 | — est $2.24M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Palvella Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Palvella Therapeutics is $230.53, +71.6% from the last close, from 9 firms rating the stock in the last 90 days.
$230.53consensus 12-month target, +71.6% from the last close
Now $134.38Avg $230.53
Low $207High $267
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | H.C. Wainwright | $246 | +83.1% |
| Sep 21 | Chardan Capital | $240 | +78.6% |
| Sep 10 | Mizuho Securities | $240 | +78.6% |
| Aug 31 | Mizuho Securities | $240 | +78.6% |
| Aug 5 | Oppenheimer | $210 | +56.3% |
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Palvella Therapeutics market cap and key statistics
Palvella Therapeutics’s market cap is $1.93B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.93B
- EPS, TTM
- −$4.85
- Gekko Fair Value
- $166.52
Trading
- Volume
- 210,296
- Avg volume, 20 days
- 234,422
- 52-week high
- $161.38
- 52-week low
- $65.93
- Shares outstanding
- 14.41M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -46.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±13.4%
Palvella Therapeutics stock news this week
Coverage of Palvella Therapeutics this week reads positive: 4 positive, 0 neutral and 0 negative headlines.
- Palvella posters estimate 154,986 U.S. DSAP patients | PVLA Stock NewsStock Titan, Oct 12
- Palvella Therapeutics Announces Three Poster PresentationsGlobeNewswire, Oct 12
- PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder TreatmentStocktwits, Oct 8
- Palvella Advances Rare-Disease Drug Toward 2027 LaunchMyChesCo, Oct 5
Palvella Therapeutics peers
Palvella Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Palvella Therapeutics stock FAQ
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $1.93B at the Oct 12, 2026 close of $134.38, with 14.41M shares outstanding.
What is the Palvella Therapeutics stock forecast?
The consensus analyst 12-month price target for Palvella Therapeutics is $230.53, +71.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Palvella Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Palvella Therapeutics is undervalued: the Oct 12, 2026 close of $134.38 is 19.3% below Gekko Fair Value of $166.52. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Palvella Therapeutics report earnings next?
Palvella Therapeutics is expected to report on Nov 10, 2026, before the market opens (29 days away). Analysts expect earnings of −$1.80 per share on revenue of $17K. Palvella Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 8.1% on average across the report.
What is Palvella Therapeutics’s 52-week high and low?
Palvella Therapeutics’s 52-week high is $161.38 and its 52-week low is $65.93; it closed at $134.38 on Oct 12, 2026, +91.7% over the past year.
Is Palvella Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Palvella Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.